The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete
Remission) of ACM (Alvocidib/Cytarabine/Mitoxantrone) compared to CM
(Cytarabine/Mitoxantrone) treatment in refractory or relapsed AML patients with demonstrated
MCL-1 dependence of ≥ 30% by mitochondrial profiling in bone marrow.
Phase:
Phase 2
Details
Lead Sponsor:
Sumitomo Dainippon Pharma Oncology, Inc Tolero Pharmaceuticals, Inc.